CN110494451B - 靶向tim-1的嵌合抗原受体 - Google Patents

靶向tim-1的嵌合抗原受体 Download PDF

Info

Publication number
CN110494451B
CN110494451B CN201880011066.7A CN201880011066A CN110494451B CN 110494451 B CN110494451 B CN 110494451B CN 201880011066 A CN201880011066 A CN 201880011066A CN 110494451 B CN110494451 B CN 110494451B
Authority
CN
China
Prior art keywords
cells
seq
car
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880011066.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110494451A (zh
Inventor
L-Z·何
H·C·小玛什
T·凯勒
T·A·斯塔德海姆
J·M·穆拉德
J·雷德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CELDARA MEDICAL LLC
Celldex Therapeutics Inc
Original Assignee
CELDARA MEDICAL LLC
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELDARA MEDICAL LLC, Celldex Therapeutics Inc filed Critical CELDARA MEDICAL LLC
Publication of CN110494451A publication Critical patent/CN110494451A/zh
Application granted granted Critical
Publication of CN110494451B publication Critical patent/CN110494451B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880011066.7A 2017-01-13 2018-01-12 靶向tim-1的嵌合抗原受体 Active CN110494451B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445976P 2017-01-13 2017-01-13
US62/445,976 2017-01-13
PCT/US2018/013551 WO2018132695A1 (en) 2017-01-13 2018-01-12 Chimeric antigen receptors targeting tim-1

Publications (2)

Publication Number Publication Date
CN110494451A CN110494451A (zh) 2019-11-22
CN110494451B true CN110494451B (zh) 2023-12-01

Family

ID=62840504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880011066.7A Active CN110494451B (zh) 2017-01-13 2018-01-12 靶向tim-1的嵌合抗原受体

Country Status (5)

Country Link
US (2) US11541076B2 (https=)
EP (1) EP3568416A4 (https=)
JP (1) JP7303749B2 (https=)
CN (1) CN110494451B (https=)
WO (1) WO2018132695A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4089116A1 (en) 2016-09-27 2022-11-16 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
EP3688032B1 (en) 2017-09-26 2025-11-05 Cero Therapeutics Holdings, Inc. Chimeric engulfment receptor molecules and methods of use
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2019222579A1 (en) * 2018-05-17 2019-11-21 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with myd88 and cd40 costimulatory domains
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
SG11202101014XA (en) * 2018-08-02 2021-02-25 Kite Pharma Inc Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
SG11202101773WA (en) * 2018-08-29 2021-03-30 Nanjing Legend Biotech Co Ltd Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
EP3902838A4 (en) 2018-12-26 2022-12-21 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
CA3139319A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
US20220265715A1 (en) * 2019-07-24 2022-08-25 Eureka Therapeutics, Inc. Chimeric antigen receptor t cells and uses thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN115103857B (zh) * 2019-12-28 2025-12-19 上海细胞治疗集团股份有限公司 表达免疫调节分子的细胞和表达免疫调节分子的系统
CA3167572A1 (en) * 2020-02-14 2021-08-19 Robbie G. MAJZNER Chimeric antigen receptors with cd2 activation
GB202004371D0 (en) * 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
CA3174094A1 (en) * 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
WO2021211510A2 (en) * 2020-04-13 2021-10-21 Affyimmune Therapeutics, Inc. Epcam antibody and car-t cells
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
EP4162058A4 (en) * 2020-06-09 2025-02-26 Hangzhou Leading Edge Pharmaceutical Ltd. COMPOSITIONS AND METHODS FOR ENHANCING THE IMMUNE RESPONSE
CN112063588A (zh) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN117042780A (zh) * 2020-10-13 2023-11-10 宾夕法尼亚大学理事会 用于mRNA治疗剂的T细胞的体内靶向
CN114149505B (zh) * 2021-01-12 2022-11-04 北京门罗生物科技有限公司 治疗b细胞相关疾病的免疫细胞、制备方法及其应用
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用
US20250304915A1 (en) * 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
CN115521917A (zh) * 2021-06-25 2022-12-27 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN113583122B (zh) * 2021-07-29 2023-08-29 武汉华美生物工程有限公司 抗人sema4d抗体及其制备方法和应用
CN115322257B (zh) * 2021-08-16 2023-05-30 上海优替济生生物医药有限公司 Bcma靶向抗体、嵌合抗原受体及其应用
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
CN115974976B (zh) * 2022-11-23 2024-06-04 华中科技大学 拮抗多肽及用于制备抗急性肾损伤药物的应用
US20250092362A1 (en) * 2023-09-15 2025-03-20 Terumo Bct, Inc. System And Methods For Producing Chimeric Antigen Receptor Cells
CN119409822B (zh) * 2024-11-01 2026-02-17 中国科学技术大学 抗体或其抗原结合片段及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059082A1 (en) * 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401869B1 (en) * 2001-06-01 2007-12-26 Biogen Idec MA Inc. Molecules and methods for inhibiting shedding of kim-1
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DK1613750T3 (en) * 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
JP5139800B2 (ja) * 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013078089A1 (en) * 2011-11-22 2013-05-30 Biogen Idec Ma Inc. Anti-tim-1 antibodies and uses thereof
CA2881981A1 (en) * 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP2939690A1 (en) * 2014-04-29 2015-11-04 Medizinische Hochschule Hannover Vaccine
JP2017533729A (ja) * 2014-10-24 2017-11-16 ベーセーエルテー ホールディングス ベーフェー Ｔ細胞ベースの免疫療法薬
WO2016115482A1 (en) * 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
SG11201708516YA (en) * 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059082A1 (en) * 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof

Also Published As

Publication number Publication date
JP7303749B2 (ja) 2023-07-05
US20190336534A1 (en) 2019-11-07
US11541076B2 (en) 2023-01-03
EP3568416A1 (en) 2019-11-20
EP3568416A4 (en) 2020-07-08
US20230355673A1 (en) 2023-11-09
WO2018132695A1 (en) 2018-07-19
CN110494451A (zh) 2019-11-22
JP2020513839A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
CN110494451B (zh) 靶向tim-1的嵌合抗原受体
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US11242376B2 (en) Compositions and methods for TCR reprogramming using fusion proteins
KR102821235B1 (ko) 선택적 단백질 발현을 위한 조성물 및 방법
EP3298033B2 (en) Compositions and medical uses for tcr reprogramming using fusion proteins
AU2016297014B2 (en) Methods for improving the efficacy and expansion of immune cells
CN115052902B (zh) 淋巴细胞-抗原提呈细胞共刺激因子及其应用
KR102859548B1 (ko) 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
KR20200069358A (ko) 키메라 항원 수용체 발현 세포의 제조 방법
KR20250061769A (ko) 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CN109562126A (zh) 嵌合抗原受体(car)、组合物及其使用方法
AU2025279705A1 (en) Combination therapy using a chimeric antigen receptor
US20210187022A1 (en) Engineered t cells for the treatment of cancer
CN113061580A (zh) 一种经修饰的免疫效应细胞及其制备方法
JP2025066746A (ja) 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
CN114729059A (zh) 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法
KR20230052289A (ko) Egfr 양성 암을 치료하기 위한 조성물 및 방법
CN120265660A (zh) 新型cd19靶向多肽和cd19定向免疫疗法
WO2025016450A1 (en) Combination of cldn18.2 and gucy2c targeted antagonist therapy
RU2841244C2 (ru) Химерные антигенные рецепторы и пути их применения
HK40045811A (en) Compositions and methods for tcr reprogramming using fusion proteins
HK40008051A (en) Compositions and methods for tcr reprogramming using fusion proteins
HK40010509A (en) Engineered t cells for the treatment of cancer
HK1252643B (en) Compositions and medical uses for tcr reprogramming using fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant